Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis

Affiliations

• ¹ Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
• ² Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
• ³ Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
• ⁴ Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Savi 6, 56126, Pisa, Italy.
• ⁵ Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, Via del Pozzo 71, Modena, Italy.
• ⁶ Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
• ⁷ Department of Medical Oncology, San Rafaele Scientific Institute IRCCS, Milan, Italy.
• ⁸ Department of Medical Oncology, University Hospital of Cagliari, Cagliari, Italy.
• ⁹ Vita-Salute San Raffaele University, Milan, Italy.
• ¹⁰ Department of Medical Oncology, San Rafaele Scientific Institute IRCCS, Milan, Italy. casadeigardini@gmail.com.
• ¹¹ Vita-Salute San Raffaele University, Milan, Italy. casadeigardini@gmail.com.